Focal Segmental Glomerulosclerosis Drugs Market Report 2026

Focal Segmental Glomerulosclerosis Drugs Market Overview

• Focal Segmental Glomerulosclerosis Drugs market size has reached to $17 billion in 2025 • Expected to grow to $27.71 billion in 2030 at a compound annual growth rate (CAGR) of 10.5% • Growth Driver: Role Of Rising Healthcare Expenditure In Fueling The Growth Of Focal Segmental Glomerulosclerosis (FSGS) Drugs Market • Market Trend: Introduction Of Novel Drugs, Gaining FDA Approval, And Orphan Drug Designation • North America was the largest region in 2025.

What Is Covered Under Focal Segmental Glomerulosclerosis Drugs Market?

Focal segmental glomerulosclerosis (FSGS) is a rare type of kidney disease that causes scarring in the kidneys' filters. Focal segmental glomerulosclerosis (FSGS) drugs refer to medications used to treat and manage the progression of the disease. The main types of focal segmental glomerulosclerosis drugs are losmapimod, SHP-627, sparsentan, tm-5484, and others. Losmapimod is an investigational drug that belongs to a class of medications known as p38 mitogen-activated protein kinase (MAPK) inhibitors. The various treatments include corticosteroids, immunosuppressive drugs, ace inhibitors, A.R. blockers, diuretics, and others through various routes of administration that include oral and parenteral. These are used by various end-users such as hospitals, homecare, specialty clinics, and others.

What Is The Focal Segmental Glomerulosclerosis Drugs Market Growth Forecast?

The focal segmental glomerulosclerosis drugs market size is expected to see rapid growth in the next few years. It will grow to $27.71 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to growth in biologics and monoclonal antibodies, rise in personalized medicine approaches, expansion of rare disease research funding, technological integration in treatment development, increase in healthcare infrastructure in emerging markets. Major trends in the forecast period include personalized medicine development, targeted therapeutics research, rare disease drug pipeline expansion, clinical trial optimization, immunomodulatory therapy advancements.

Global Focal Segmental Glomerulosclerosis Drugs Market Segmentation

1) By Type: Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types 2) By Treatment: Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments 3) By Route of Administration: Oral, Parenteral 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

What Is The Driver Of The Focal Segmental Glomerulosclerosis Drugs Market?

Rising healthcare expenditure is expected to propel the growth of the focal segmental glomerulosclerosis (FSGS) drugs market going forward. Healthcare expenditure refers to the total amount of money spent on healthcare services and related goods and activities within a specific healthcare system or economy over a defined period. Rising healthcare expenditures can be helpful for the development and availability of drugs for focal segmental glomerulosclerosis (FSGS). They increase research funding and clinical trials, which help to improve drug output. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based Institute for Health Information, in 2023, total health spending in Canada is projected to reach $344 billion, equating to $8,740 per person. This marks a 2.8% increase compared to the previous year, which saw only a 1.5% growth in health spending in 2022, indicating a notable rebound in healthcare investment. Therefore, rising healthcare expenditures are driving the growth of the focal segmental glomerulosclerosis (FSGS) drugs market.

Key Players In The Global Focal Segmental Glomerulosclerosis Drugs Market

Major companies operating in the focal segmental glomerulosclerosis drugs market are Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio, Alexion Pharmaceuticals, Bayer AG, Novartis AG, Pfizer Inc., Johnson and Johnson Ltd., Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Fresenius Kabi Ltd., Gilead Sciences Inc, Reata Pharmaceuticals, Amgen Inc

Global Focal Segmental Glomerulosclerosis Drugs Market Trends and Insights

Major companies operating in the focal segmental glomerulosclerosis (FSGS) market are increasingly focusing on product development and innovation to provide reliable products to their customers and strengthen their market position. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, launched FILSPARI, for focal segmental glomerulosclerosis (FSGS), which was approved by the Food and Drug Administration (FDA), a US-based federal agency. It is an oral medicine for treating IgA nephropathy (IgAN). It is the first and only non-immunosuppressive treatment for lowering proteinuria in IgAN, a rare kidney disease. Additionally, FILSPARI has been given orphan drug designation in the United States and Europe for treating IgAN and focal segmental glomerulosclerosis (FSGS).

What Are Latest Mergers And Acquisitions In The Focal Segmental Glomerulosclerosis Drugs Market?

In October 2023, Amgen, a US-based biotechnology company acquired Horizon Therapeutics plc for $27.8 billion. Through this acquisition, Amgen intends to strengthen Horizon's product range, featuring key medicines such as Tepezza and Krystexxa, which are used for treating rare inflammatory conditions. Horizon Therapeutics is a US-based biotechnology company that involved in focal segmental glomerulosclerosis drugs.

Regional Insights

North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Focal Segmental Glomerulosclerosis Drugs Market?

The focal segmental glomerulosclerosis (FSGS) drugs market consists of sales of rituximab, statins, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Focal Segmental Glomerulosclerosis Drugs Market Report 2026?

The focal segmental glomerulosclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the focal segmental glomerulosclerosis drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.